1. Scrip
  2. >>Therapy Areas

BI And Lilly Eye Acute Heart Failure Opportunity For Jardiance

First SGLT Inhibitor To Work In These Patients

 
• By Kevin Grogan

Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.

heart failure illustration
• Source: Archive

Days after US regulators granted a swift review for Jardiance for another chronic heart failure indication, Boehringer Ingelheim GmbH and Eli Lilly and Company have presented data showing that their blockbuster SGLT2 inhibitor could benefit adults hospitalized with acute heart failure.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas